secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001493152-25-003019
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.03, 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Interpace restructures debt and cuts workforce after CMS drops PancraGEN coverage
--------------------------------------------------------------------------------

- Fourth Amendment: monthly $500k principal payments Feb-Jun 2025, interest-only Jul-Dec, final balance due Dec 31, 2025; 1% restructuring fee paid on Jan 17, 2025.
- Board approved restructuring plan Jan 14, 2025 due to CMS ending PancraGEN coverage (announced Jan 9, 2025).
- Workforce reduction; severance costs estimated $0.8M–$1.0M, primarily recorded in Q1 2025.
- Expected annual cost savings of $12.5M–$14.5M, expected to offset approximately one-third of revenue loss from PancraGEN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315225003019/0001493152-25-003019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315225003019/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-003019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer